Drugs / EBNK-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07410676 | Feb 2026 → Dec 2028 expected | breast cancer, colorectal cancer, cutaneous melanoma, esophageal cancer +9 | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBNK-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410676 ↗ |
| Modality | Cell therapy | “EBNK-001 (Allogeneic NK Cells)” NCT07410676 ↗ |